Scientists in South Africa are making rhino horns radioactive to fight poaching
Under the collaborative project involving the University of the Witwatersrand, nuclear energy officials and conservationists, five rhinos were injected in what the university hopes will be the start of a mass injection of the declining rhino population.
They're calling it the Rhisotope Project.
Last year, about 20 rhinos at a sanctuary were injected with isotopes in trials that paved the way for Thursday's launch. The radioactive isotopes even at low levels can be recognized by radiation detectors at airports and borders, leading to the arrest of poachers and traffickers.
Researchers at Witwatersrand's Radiation and Health Physics Unit say that tests conducted in the pilot study confirmed that the radioactive material was not harmful to the rhinos.
'We have demonstrated, beyond scientific doubt, that the process is completely safe for the animal and effective in making the horn detectable through international customs nuclear security systems,' said James Larkin, chief scientific officer at the Rhisotope Project.
'Even a single horn with significantly lower levels of radioactivity than what will be used in practice successfully triggered alarms in radiation detectors,' said Larkin.
The tests also found that horns could be detected inside full 40-foot shipping containers, he said.
The International Union for Conservation of Nature estimates that the global rhino population stood at around 500,000 at the beginning of the 20th century but has now declined to around 27,000 due to continued demand for rhino horns on the black market.
South Africa has the largest population of rhinos with an estimated 16,000 but the country experiences high levels of poaching with about 500 rhinos killed for their horns every year.
The university has urged private wildlife park owners and national conservation authorities to have their rhinos injected.
___
AP Africa news: https://apnews.com/hub/africa
Associated Press, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
7 hours ago
- Medscape
Novel Tuberculosis Shots May Benefit HIV-Positive Population
TOPLINE: A two-dose regimen of the M72/AS01 E-4, a recombinant fusion protein tuberculosis vaccine candidate, demonstrated acceptable safety and immunogenicity in virally suppressed, antiretroviral therapy (ART)-treated adolescents and adults living with HIV, showing strong antibody and CD4 T-cell responses. METHODOLOGY: Researchers conducted a randomized, phase 2 trial in South Africa to evaluate the safety and immunogenicity of the investigational M72/AS01 E-4 tuberculosis vaccine, derived from two Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A) and AS01 E-4 adjuvant, in people living with HIV. tuberculosis vaccine, derived from two Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A) and AS01 adjuvant, in people living with HIV. Overall, 401 participants — each on ART for ≥ 3 months with HIV viral loads < 200 copies per mL and CD4 T-cell count ≥ 200 cells per µL — were randomly assigned to receive either the M72/AS01 vaccine (n = 201; mean age, 29.4 years; 87% women) or placebo (n = 200; mean age, 29.6 years; 88% women), on days 1 and 29. Primary endpoints were the vaccine's reactogenicity and safety, assessed via solicited adverse events (AEs) within 7 days, unsolicited AEs within 28 days, and serious AEs throughout the trial. Immunogenicity was evaluated by measuring M72-specific immunoglobulin G antibody concentrations on days 1, 29, 57, 210, and 390, as well as M72-specific CD4 and CD8 T-cell responses. TAKEAWAY: Vaccine-related AEs occurred more frequently in the vaccine group (12%) than in the placebo group (6%), primarily due to a higher rate of injection-site reactions in the vaccine group (8% vs 1%). Two severe unsolicited AEs related to the vaccine were reported — a case each of dizziness and injection-site erythema, but no participant discontinued the trial or died due to AEs. Nine serious AEs occurred — four in the vaccine group (COVID-19, tibia fracture, spontaneous abortion, or psychotic disorder) and five in the placebo group (COVID-19, anal abscess, spontaneous abortion, substance-induced psychotic disorder, or physical assault); none was related to the vaccine. In the vaccine group, the geometric mean concentration of antibodies against M72 increased from the baseline level to 13.28 EU/mL by day 29, peaked at 479.70 EU/mL by day 57, and then declined to 32.43 EU/mL by day 390 — yet remained above prevaccination levels. No such increase was observed in the placebo group. The M72-specific CD4 T cells expressing interferon gamma or interleukin-2 was significantly higher in the vaccine group than in the placebo group at both day 57 and day 390 (P < .0001). IN PRACTICE: 'In conclusion, a two-dose regimen of M72/AS01 E-4 vaccine, administered 1 month apart, was well-tolerated, with an acceptable safety profile, and was immunogenic in virally suppressed, ART-treated people living with HIV aged 16-35 years,' the authors wrote. SOURCE: The study was led by Alemnew F. Dagnew, MD, Gates Medical Research Institute, Cambridge, Massachusetts. It was published online on July 1, 2025, in The Lancet HIV. LIMITATIONS: The trial population was restricted to people living with HIV who achieved viral suppression through ART, potentially limiting the generalizability of the results to those not on ART, not adhering to treatment, or newly diagnosed with HIV. Additionally, most participants were women, which may have affected overall trial outcomes given the higher risk for tuberculosis among men. DISCLOSURES: The study was funded by the Gates Foundation and the Wellcome Trust. Several authors were employees of the Gates Medical Research Institute during the trial. Some authors also received financial aid from other organizations, including Wellcome, UK Research and Innovation, Cancer Research UK, and TB Alliance. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
13 hours ago
- Yahoo
Gabon forest cave reveals clues about prehistoric central Africa
In Gabon's sprawling forest, archaeologists dig for ancient clues that could unlock the secrets of how prehistoric humans lived and interacted in the changing landscape of central Africa. Two billion years ago, the eastern Gabonese region of Lastourville was covered by a vast ocean. But that has long given way to dense forest and dolomite cliffs dotted with caves, within which scientists have unearthed traces of human life dating back to 25,000 years BC. Off the beaten track even for archaeologists, the Youmbidi rock shelter, a cavern typical of those chosen by prehistoric humans to set up their homes, is the focus for French geoarchaeologist Richard Oslisly's team. Among their finds: a stone tool which could have been used for cutting or making fibres dating to before 10,000 BC. An arrowhead has also been unearthed, as has a collection of dolomite, quartz and jasper shards, cut up to 10,000 years ago by the cave's inhabitants. "The vast majority of research in Africa has taken place in open landscapes such as the Sahara, Sahel or Egypt," said Oslisly, who has spent 45 years working in central Africa. "They said to me 'there's nothing in the forest' (but) I took up the challenge of finding out what was happening there," he added. "We realise there is a very close relationship between man and nature in these forests, where people have lived for a very long time," Oslisly said. The Youmbidi cave -- where scientists have recorded 12,000 years of continuous human habitation -- is an enticing spot for the archeologists. "We don't know at all how these people lived, what their way of life was, what their names were, what their languages were," said Geoffroy de Saulieu from France's IRD Research Institute for Development. "Our research will help us to know a little more," he added. - Jigsaw puzzle - After a month of digging and careful sorting of every stone, charcoal remnant, bone and other treasure buried below the cave, the team has elements to help decipher the past. De Saulieu said it was like a jigsaw puzzle. "You have to... gather the smallest clues, place them end to end to gradually reconstruct a whole universe that has disappeared and which is, nevertheless, at the origin of the way of life in central Africa today," said the expert, currently attached to the National Agency of National Parks of Gabon. One of the oldest bits of pottery found in central Africa, which dated to more than 6,500 years ago, is among this year's finds. Human-looking teeth that could allow DNA to be extracted in what would prove a significant leap in research have also excited archaeologists. And, like all the artefacts, a bead likely made between 3,300 and 4,900 years ago from a snail shell also offers precious insight as a "very humble but beautiful witness" of the epoch in question. Dispelling stereotypical images of prehistoric Man, it suggests people had "real customs, a real civilisation and art of living," de Saulieu said. The pottery "shows that these societies weren't immobile, they had launched themselves into technical innovations", he added. The discoveries fan his fascination for the richness of "the social life which existed in the region's forests". - Resilience - Glimpses into an ancient lost world can also be useful for tackling present-day challenges, the experts said. During the Holocene period which dates back the past 12,000 years, "central Africa has experienced very significant changes in climate, hydrology and vegetation," said paleoclimatologist Yannick Garcin, also from the IRD and involved in the Youmbidi dig. The hope is that the cave will unlock an understanding of "the resilience of human populations in the past and how they were able to adapt to climate changes that could have been drastic", he said. Central Africa for that reason "deserves major development in terms of research", Oslisly argued. Understanding what happened in prehistoric times can help scientists today react to modern-day issues, he added. "Good studies on the relationship between Man and the environment in the past will allow us to react better to the environmental changes that are ahead of us," he said. lnf/hpn/kjm/cw
Medscape
a day ago
- Medscape
Can Treating Siblings Aid Azithromycin's Effect on Infants?
TOPLINE: Mass administration of azithromycin to both infants aged 1-11 months and children aged 12-59 months reduced infant mortality compared with treating infants alone. Although the interaction effect was not statistically significant, mortality appeared to be lower among infants living with treated older siblings. METHODOLOGY: In this secondary analysis of a cluster-randomized trial, researchers evaluated whether mass azithromycin administration reduced infant mortality and examined how that benefit varied when an older sibling in the same household also received azithromycin. They included 98,969 infants aged 1-11 months with a minimum weight of 3 kg and no known macrolide allergies who received biannual 20-mg/kg doses of oral azithromycin or placebo from November 2020 to July 2023 in Niger. Participants were divided into three arms: infants and children aged 1-59 months on azithromycin (child arm), infants aged 1-11 months on azithromycin and children aged 12-59 months on placebo (infant arm), and children aged 1-59 months on placebo (placebo arm). The primary outcome was the community-level rate of all-cause mortality among infants aged 1-11 months after 2 years of azithromycin distribution, stratified by the presence or absence of older siblings (12-59 months) in the household. TAKEAWAY: The mortality rate of infants per 1000 person-years at risk was lowest in the child arm at 18.5 deaths (95% CI, 16.7-20.4) compared with 22.3 deaths (95% CI, 20.0-24.7) in the infant arm and 23.9 deaths (95% CI, 21.6-26.2) in the placebo arm. In communities receiving azithromycin vs placebo, mortality among infants aged 1-11 months declined by 23% (95% CI, 11%-33%). Of this reduction, 23.5% (95% CI, 1.2%-72.7%) was attributable to treating infants directly, while 76.5% (95% CI, 27.3%-98.8%) resulted from also treating children aged 12-59 months. Among infants with older siblings, the incidence rate ratio comparing child and infant arms was 0.78 (95% CI, 0.65-0.93), while it was 0.91 (95% CI, 0.73-1.15) for those without siblings (P for interaction = .26). IN PRACTICE: 'The main trial results support implementation of azithromycin MDA [mass drug administration] to infants and children aged 1-59 months to achieve the greatest benefit. The analyses presented herein further support this conclusion and suggest that the spillover mechanism may include treating older siblings,' the authors wrote. SOURCE: This study was led by Ahmed M. Arzika, MPH, Centre de Recherche et d'Intervention en Santé Publique, Birni N'Gaoure, Niger. It was published online on July 10, 2025, in JAMA Network Open. LIMITATIONS: Limited statistical power restricted the detection of interaction effects in subgroup analyses. Even in high ‐ mortality settings, deaths remain too infrequent to reveal significant differences between subgroups. The large simple trial design prevented the evaluation of cause-specific mortality. Thus, analysis of specific causes of death likely associated with spillover effects of the mass administration of azithromycin could not be determined. DISCLOSURES: This study received support from the Bill & Melinda Gates Foundation and National Institute of Allergy and Infectious Diseases of the National Institutes of Health. Pfizer Inc donated the azithromycin and placebo used in the trial. A few authors reported receiving grants from the funding organization. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
